直接抗病毒药物时代下丙型肝炎研究面临的挑战

摘要

HCV是全球范围内导致慢性病毒性肝炎的重要病原体之一。HCV长期隐匿性感染可能会引发肝纤维化、肝硬化和肝癌等晚期肝病。干扰素和利巴韦林联合用药广泛用于HCV感染的治疗，但这一疗法治疗效果有限，并且具有很强的副作用。HCV小分子直接抗病毒药物（DAA）的出现大大提高了治疗效果，并有望最终完全取代干扰素疗法。然而慢性丙型肝炎治疗进入DAA时代并不意味着丙型肝炎问题已经解决，丙型肝炎研究依然面对诸多挑战。%Hepatitis C virus (HCV)is an important human pathogen that causes chronic viral hepatitis worldwide.HCV infection,often persistent and asymptomatic,could lead to liver fibrosis/cirrhosis and hepatocellular carcinoma.The interferon/ribavirin therapy has been widely used for treating chronic hepatitis C,but it is not always effective and has strong side effects.The development of small-molecule di-rect antiviral agents (DAA)has greatly improved the curing efficiency of chronic hepatitis C therapeutics and will likely replace the interfer-on-based therapy in the future.However,these developments do not necessarily suggest that the problems of chronic hepatitis C have been completely solved.The HCV research is still facing many challenges in this new DAA era.